<SEC-DOCUMENT>0001193125-26-010480.txt : 20260112
<SEC-HEADER>0001193125-26-010480.hdr.sgml : 20260112
<ACCEPTANCE-DATETIME>20260112163450
ACCESSION NUMBER:		0001193125-26-010480
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20260106
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260112
DATE AS OF CHANGE:		20260112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				883099146
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		26527217

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		302-274-8744

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d97670d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20260106" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-548">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-01-06_to_2026-01-06">0001937653</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="zyme-20260106.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-01-06_to_2026-01-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-06</xbrli:startDate> <xbrli:endDate>2026-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-559">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt:datemonthdayyearen" id="ixv-560">January&#160;6, 2026</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-561">Zymeworks Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:stateprovnameen" id="ixv-562">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-563">001-41535</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-564">88-3099146</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-565">108 Patriot Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-566">Suite A</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-567">Middletown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:stateprovnameen" id="ixv-568">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-569">19709</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-570">(302)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-571">274-8744</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:boolballotbox" id="ixv-572">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:boolballotbox" id="ixv-573">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:boolballotbox" id="ixv-574">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:boolballotbox" id="ixv-575">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-576">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-577">ZYME</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:exchnameen" id="ixv-578">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-01-06_to_2026-01-06" format="ixt-sec:boolballotbox" id="ixv-579">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;11, 2026, Zymeworks Inc. (the &#8220;Company&#8221;) announced certain information relating to the Company&#8217;s financial condition as of December&#160;31, 2025, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable securities, of approximately $270.6&#160;million. The Company also announced that, based on current operating plans and existing cash resources, and assuming full execution of the $125.0&#160;million share repurchase plan and receipt of anticipated regulatory milestone payments of $440.0&#160;million associated with potential regulatory approvals of <span style="font-style:italic">Ziihera</span> in GEA in the United States, Europe, Japan, and China, the Company believes it is positioned to fund planned operations beyond 2028 (such information, the &#8220;Financial Condition Information&#8221;). The Financial Condition Information is set forth in a press release issued by the Company on January&#160;11, 2026, including under the section titled &#8220;Operational and Cash Runway Guidance&#8221;. The preliminary and unaudited estimate of cash resources is based on management&#8217;s initial analysis of operations for the quarter and year ended December&#160;31, 2025, and is subject to further internal review and audit by the Company&#8217;s external auditors. A copy of this press release is attached hereto as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release attached hereto as Exhibit 99.1 is incorporated herein by reference, except for the Financial Condition Information, including the information set forth under the section titled &#8220;Operational and Cash Runway Guidance&#8221;, as well as any hyperlinked information, which information is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Appointment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2026, the board of directors (the &#8220;Board&#8221;) of the Company, upon recommendation from the nominating and corporate governance committee of the Board appointed Mr.&#160;Brian Cherry as a Class&#160;II director of the Company effective January&#160;12, 2026, with a term expiring at the Company&#8217;s 2026 annual general meeting of stockholders. Mr.&#160;Cherry will not be named to any committees of the Board in connection with his appointment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no transactions and no proposed transactions between Mr.&#160;Cherry or any member of his immediate family and the Company or its subsidiaries that would require disclosure under Item 404(a) of <span style="white-space:nowrap">Regulation&#160;S-K&#160;under</span> the Securities Act, and there is no other arrangement or understanding between Mr.&#160;Cherry and any other person or entity pursuant to which Mr.&#160;Cherry was appointed as a director of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Cherry will participate in the Company&#8217;s standard compensation plan <span style="white-space:nowrap">for&#160;non-employee&#160;directors,</span> including initial equity awards consisting of a stock option to purchase 23,000 shares of common stock and 15,400 restricted stock units (&#8220;RSUs&#8221;), each of which awards will be granted on January&#160;12, 2026. The standard compensation plan for non-employee directors is described in Item 8.01 below, which description is incorporated herein by reference. Mr.&#160;Cherry will also enter into the Company&#8217;s standard form of indemnification agreement for directors and executive officers (&#8220;Indemnification Agreement&#8221;), the form of which was filed as Exhibit 10.40 to the Company&#8217;s Annual report on Form <span style="white-space:nowrap">10-K</span> filed with the Securities and Exchange Commission on March&#160;5, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A press release announcing Mr.&#160;Cherry&#8217;s appointment to the Board is attached hereto as Exhibit 99.2 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of Chief Financial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2026, Ms.&#160;Leone Patterson was terminated from her positions as Executive Vice President, Chief Business Officer and Chief Financial Officer, including as the Company&#8217;s principal financial officer and principal accounting officer, effective as of January&#160;9, 2026. Ms.&#160;Patterson will remain an employee of the Company until January&#160;31, 2026. Pursuant to the terms of Ms.&#160;Patterson&#8217;s employment agreement, because Ms.&#160;Patterson&#8217;s employment agreement with the Company was terminated without cause, she is eligible to receive certain termination benefits subject to her entry into a separation agreement with the Company. For additional information on Ms.&#160;Patterson&#8217;s termination benefits, please refer to the summary of Ms.&#160;Patterson&#8217;s employment agreement under &#8220;Executive Compensation&#8212;Executive Employment Arrangements and Potential Payments upon Termination or Change in Control&#8212;Executive Employment Arrangements&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A filed in connection with the Company&#8217;s 2025 annual meeting of stockholders,&#160;filed&#160;with the Securities and Exchange Commission on <span style="text-decoration:underline">November 10, 2025,</span> which information is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&#160;Patterson&#8217;s termination from her positions as Executive Vice President, Chief Business Officer and Chief Financial Officer, including her role as principal financial officer and principal accounting officer, as well as her anticipated separation from employment on January&#160;31, 2026 are not due to any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Ms.&#160;Patterson&#8217;s removal, effective January&#160;9, 2026, the Board appointed Mr.&#160;Kenneth&#160;Galbraith, the Company&#8217;s current Chair of the Board, President and Chief Executive Officer, as the Company&#8217;s interim Chief Financial Officer. In connection with this appointment, Mr.&#160;Galbraith will continue in his roles as Chair of the Board, President and Chief Executive Officer and assume the duties of the Company&#8217;s principal financial officer and principal accounting officer, until his successor is appointed or until his earlier resignation or removal. The Company has initiated a search for a new Chief Financial Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Galbraith is 63 years old and has served as the Company&#8217;s Chief Executive Officer and Chair of the Board since January 2022. In addition, Mr.&#160;Galbraith has served as the Company&#8217;s President since June 2023 and previously served as the Company&#8217;s President from January 2022 to August 2022, and served as our interim Chief Financial Officer from April 2024 to September 2024. Mr.&#160;Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Investment Management Limited (&#8220;SIML&#8221;, a subsidiary of Syncona Limited, a company that builds a portfolio of life sciences businesses), from April 2021 until January 2022. He has served as an advisor to SIML since May 2023 and as a director of SIML since November 2024, including as Chair since February 2025.&#160;He&#160;served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr.&#160;Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr.&#160;Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr.&#160;Galbraith received his B.Comm. from the University of British Columbia. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensatory and other material terms of Mr.&#160;Galbraith&#8217;s employment with the Company will remain unchanged in connection with the foregoing. For information regarding Mr.&#160;Galbraith&#8217;s existing compensation arrangements, please refer to the information contained in the section titled &#8220;Executive Compensation&#8212;Executive Employment Arrangements and Potential Payments upon Termination or Change in Control&#8212;Executive Employment Arrangements&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A filed in connection with the Company&#8217;s 2025 annual meeting of stockholders,&#160;filed&#160;with the Securities and Exchange Commission on <span style="text-decoration:underline">November&#160;10, 2025,</span> which information is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&#160;Galbraith and any other persons pursuant to which he was appointed interim Chief Financial Officer of the Company. There are also no family relationships between Mr.&#160;Galbraith and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appointment of Chief Operating Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;6, 2026, the Company appointed Mr.&#160;Mark Hollywood, age 56, the Company&#8217;s current Executive Vice President and Head of Technical and Manufacturing Operations, as Executive Vice President and Chief Operating Officer of the Company, effective January&#160;9, 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hollywood joined Zymeworks in March 2019 as Senior Vice President, Technical and Manufacturing Operations, and was promoted to Executive Vice President and Head of Technical and Manufacturing Operations in January 2023. Mr.&#160;Hollywood has over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr.&#160;Hollywood has a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr.&#160;Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&#160;Hollywood and any other persons pursuant to which he was appointed Chief Operating Officer. There are also no family relationships between Mr.&#160;Hollywood and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) <span style="white-space:nowrap">of&#160;Regulation&#160;S-K.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Mr.&#160;Hollywood&#8217;s appointment as Chief Operating Officer, his annual base salary was increased from $475,000 to $525,000, with retroactive effectiveness as of January&#160;1, 2026, is eligible for a discretionary bonus of up to 45% of his base salary. Mr.&#160;Hollywood was also granted an equity award consisting of (i) 70,000 options to purchase common stock that will vest 25% on the <span style="white-space:nowrap">one-year</span> anniversary of the grant date, with 1/36th of the remaining shares vesting on each monthly anniversary thereafter, (ii) 47,000 RSUs vesting as to 25% of the underlying shares on each anniversary of the grant date, and (iii) 33,000 performance stock units (at target) vesting in accordance with certain performance and service-based vesting terms and conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hollywood previously entered into an employment agreement with the Company&#8217;s subsidiary Zymeworks Biopharmaceuticals Inc., effective March&#160;25, 2019 (the &#8220;Employment Agreement&#8221;). Pursuant to the terms of the Employment Agreement, Mr.&#160;Hollywood is entitled to the following compensation and benefits, as such terms have been modified as described in the preceding paragraph: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an annual base salary, currently $525,000, with eligibility to earn an annual discretionary bonus, currently of up to 45% of his annual base salary, based upon the achievement of certain Company goals determined by the Board of Directors pursuant to the Company&#8217;s Executive Incentive Compensation Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">eligibility to participate in our employee benefit plans, policies and arrangements, as well as reimbursement for certain fees and costs related to membership in certain professional associations and professional development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if we terminate Mr.&#160;Hollywood&#8217;s employment without cause, then Mr.&#160;Hollywood will be eligible to receive (a)&#160;twelve months of notice or the equivalent of twelve months of base salary and benefits continuation as of the date notice is given, or any combination thereof that totals twelve months of combined notice and base salary plus (b)&#160;an additional one month of notice or the equivalent of one month of base salary and benefits continuation as of the date notice is given, or any combination thereof, for each completed year of service beginning with the fourth year of service, up to a total maximum of eighteen months. Such payments will be subject to Mr.&#160;Hollywood entering into a valid separation and release agreement with the Company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if Mr.&#160;Hollywood&#8217;s employment is terminated by us without cause on or within twelve months following a change of control (as defined in the Employment Agreement), Mr.&#160;Hollywood will be eligible to receive as severance (x)&#160;eighteen months base salary and benefits continuation as at the termination date, and (z)&#160;full vesting acceleration of all unvested and outstanding stock options or other equity grants as of the date of termination. Such payments will be subject to Mr.&#160;Hollywood entering into a valid separation and release agreement with the Company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hollywood is a party to an Indemnification Agreement with the Company. Except as described above, the compensatory and other material terms of Mr.&#160;Hollywood&#8217;s employment will remain unchanged in connection with his appointment as Executive Vice President and Chief Operating Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which will be filed as an exhibit to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2025. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee&#160;Director</span> Compensation Policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board maintains a compensation policy for its <span style="white-space:nowrap">non-employee</span> directors providing for cash and equity compensation, the terms of which policy are periodically evaluated and revised based upon advice from the independent compensation consultant to the Board&#8217;s compensation committee (the &#8220;Compensation Committee&#8221;). On January&#160;9, 2026, upon advice from the independent compensation consultant and recommendation from the Compensation Committee, the Board approved an amended and restated <span style="white-space:nowrap">non-employee</span> director compensation policy (as amended, the &#8220;Amended and Restated Director Compensation Policy&#8221;), providing for revised cash and equity compensation to <span style="white-space:nowrap">non-employee</span> directors, effective as of January&#160;1, 2026, which changes adjust the Board&#8217;s compensation program based in part upon <span style="white-space:nowrap">the&#160;non-employee&#160;director</span> compensation practices of the Company&#8217;s peer group. The key revisions effected by the Amended and Restated Director Compensation Policy include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Beginning January&#160;1, 2026, the annual cash retainer fee for service on the Board increased from $40,000 to $45,000 and the additional annual cash retainer fee for service as Lead Independent Director increased from $25,000 to $30,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The initial equity award for any new <span style="white-space:nowrap">non-employee</span> directors, to be granted on or about the time of the director joining the Board, was changed from an option to purchase 62,000 shares of Company common stock to equity awards consisting of an option to purchase 23,000 shares of common stock and 15,400 RSUs. 1/36th of the shares subject to the option will vest on each monthly anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service, and the RSUs will vest as to 1/3 of the underlying shares on each annual anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The annual equity grant to continuing <span style="white-space:nowrap">non-employee</span> directors, was changed from an option to purchase 31,000 shares of Company common stock to equity awards consisting of an option to purchase 11,500 shares of common stock and 7,700 RSUs. The options and RSUs each vest as to 100% of the shares subject to the option or the RSUs, as applicable, on the <span style="white-space:nowrap">one-year</span> anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service through such date. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the foregoing amendments, the Amended and Restated Director Compensation Policy provides for the following cash and equity compensation to the <span style="white-space:nowrap">Company&#8217;s&#160;non-employee&#160;directors:</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Compensation </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:19%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Effective&#160;January&#160;1,&#160;2026</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Amount ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board of Directors:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lead Independent Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominating and Corporate Governance Committee:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about the time a <span style="white-space:nowrap">new&#160;non-employee&#160;director</span> joins the Board, he or she will be granted an initial equity award consisting of (A)&#160;an option grant to purchase 23,000 shares of common stock, with a vesting schedule of 1/36th of the total shares of common stock underlying such option vesting on each monthly anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service through the applicable vesting date, and (B)&#160;a grant of 15,400 RSUs with a vesting schedule of 1/3 of the RSUs vesting on each annual anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service through the applicable vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In <span style="white-space:nowrap">addition,&#160;non-employee&#160;directors</span> will be granted an annual equity grant consisting of (A)&#160;an option grant to purchase 11,500 shares of common stock, with a vesting schedule of 100% of the total shares of common stock underlying such option vesting on the <span style="white-space:nowrap">one-year</span> anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service through the applicable vesting date; and (B)&#160;a grant of 7,700 RSUs with a vesting schedule of 100% of the RSUs vesting on the <span style="white-space:nowrap">one-year</span> anniversary of the grant date, subject to the <span style="white-space:nowrap">non-employee</span> director&#8217;s continued service through the applicable vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-termination exercise period for vested options held by departing directors remains three years following the director&#8217;s cessation of service (or, if earlier, upon the expiration of the option). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Retirement of Chief Medical Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;12, 2026, the Company announced the retirement of Dr.&#160;Jeffrey Smith, the Company&#8217;s Executive Vice President and Chief Medical Officer. Dr.&#160;Smith&#8217;s last day will be January&#160;31, 2026, after such time, Dr.&#160;Smith will continue to provide services as an adviser for a transitional time period. On January 6, 2026, the Company appointed Dr.&#160;Sabeen Mekan as Senior Vice President and Chief Medical Officer, effective February&#160;1, 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Update </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;11, 2026, the Company issued a press release announcing a corporate update on its strategic priorities and other matters. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference, except for the Financial Condition Information, including the information set forth under the section titled &#8220;Operational and Cash Runway Guidance&#8221;, as well as any hyperlinked information, which information is furnished as described under Item 2.02 above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K&#160;contains&#160;certain</span> forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. Forward-looking statements are identified by such words as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate&#8221; and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company&#8217;s plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the Company&#8217;s preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable securities, and the Company&#8217;s anticipated funding of its current operations and related expected timelines. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date. Furthermore, the Company is in the process of finalizing its financial results for the fourth quarter and fiscal year ended December&#160;31, 2025, and therefore the Company&#8217;s finalized and audited results and final analysis of those results are not yet available. The preliminary <span style="white-space:nowrap">expectations&#160;regarding&#160;year-end&#160;cash,&#160;cash</span> equivalents, and marketable securities are the responsibility of management, are subject to management&#8217;s review and actual results could differ from management&#8217;s expectations. The actual results are also subject to audit by the Company&#8217;s independent registered public accounting firm and no assurance is given by the Company&#8217;s independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December&#160;31, 2025, based on the foregoing estimates. </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d97670dex991.htm">Press Release, dated January&#160;11, 2026. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d97670dex992.htm">Press Release, dated January&#160;12, 2026. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded as Inline XBRL document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">ZYMEWORKS INC.</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;12, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Kenneth Galbraith</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chair of the Board of Directors, President, Chief Executive Officer and interim Chief Financial Officer</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d97670dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g97670g0111114420980.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks Outlines Strategic Priorities and Outlook for 2026 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Positive Phase 3
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-GEA-01</FONT></FONT> results for Ziihera</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> (zanidatamab-hrii) in first-line HER2-positive (HER2+)
gastroesophageal adenocarcinoma (GEA) presented at ASCO GI </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Up to $440.0</I><I></I><I>&nbsp;million in milestone payments eligible to be earned related to regulatory
approvals of Ziihera in GEA in the United States, Europe, Japan, and China</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Company well-positioned to execute new strategy compounding long-term value by integrating royalty growth,
strategic acquisitions, and continued internal R&amp;D innovation</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>$125.0</I><I></I><I>&nbsp;million share repurchase plan announced in November 2025 available to reduce share
count</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cash, cash equivalents, and marketable securities of approximately $270.6</I><I></I><I>&nbsp;million
(unaudited) as of December</I><I></I><I>&nbsp;31, 2025, combined with anticipated regulatory milestone payments related to potential approvals of Ziihera in GEA, expected to provide cash runway beyond 2028</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Company to present at the J.P. Morgan Annual Healthcare Conference on Wednesday,
January</I><I></I><I>&nbsp;14, 2026 at 3:00 pm Pacific Time (PT) </I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vancouver, British Columbia (January 11, 2026)</B> &#8211;
<U>Zymeworks Inc</U>. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key
milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;2025 was a pivotal and transformative year for Zymeworks,&#8221; said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. &#8220;We
strengthened our leadership capabilities with the addition of seasoned biotech executives and a refreshed Board, delivered strong execution across our preclinical, clinical and partnered programs, and demonstrated the value of our integrated
business model. We enter 2026 with a solid financial foundation, visibility of substantial future cash flows from partnered programs and a clear strategy to compound long-term value through integrating royalty growth, disciplined internal R&amp;D
innovation, and strategic acquisitions.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key 2025 Accomplishments: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#8217; progress in 2025 included significant clinical advancement, strengthened leadership, and increased financial flexibility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partnered Programs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Positive results</U> from the Phase 3
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-GEA-01</FONT></FONT> trial evaluating Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(zanidatamab-hrii) in combination with chemotherapy, with or
without the <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor Tevimbra<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (tislelizumab), as a first-line treatment for HER2+ locally advanced or metastatic GEA. <I>Ziihera</I> plus
chemotherapy showed a clinically meaningful and statistically significant improvement in progression-free survival (PFS) versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for
overall survival (OS) at the first OS interim analysis; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulatory approvals of zanidatamab in China by the <U>National Medical Products Administration</U> (NMPA) and
European Commission approval, in previously treated unresectable or metastatic HER2+ biliary tract cancer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our partner, J&amp;J Innovative Medicine (J&amp;J), reported Phase 1 trial results at ASCO 2025 for pasritamig <FONT
STYLE="white-space:nowrap">(JNJ-78278343),</FONT> a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> <FONT STYLE="white-space:nowrap">T-cell</FONT> engaging bispecific antibody targeting human
kallikrein 2 (KLK2) expressed on the surface of prostate cancer cells. In September, J&amp;J announced initiation of several Phase 3 trials evaluating pasritamig in both monotherapy and combination regimens; and, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$69.6&nbsp;million in milestone payments earned from BMS, GSK, J&amp;J, Daiichi Sankyo, and BeOne Medicines from
zanidatamab and legacy platform collaboration agreements. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Wholly-owned Pipeline: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
<U>global studies</U> for ZW251, a novel <FONT STYLE="white-space:nowrap">glypican-3</FONT> (GPC3)-targeted antibody-drug conjugate (ADC) incorporating Zymeworks&#8217; proprietary topoisomerase 1 inhibitor payload, ZD06519, for the treatment of
hepatocellular carcinoma (<U>NCT07164313</U>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presentation of <U>preliminary Phase 1 results</U> for ZW191, an ADC targeting folate receptor-alpha,
demonstrating responses across dose levels and supporting a wide therapeutic index of Zymeworks&#8217; novel ADC platform, with 64% overall response rate in gynecological cancers at doses &#8805;6.4mg/kg. Dose optimization of ZW191 in ovarian cancer
initiated in <FONT STYLE="white-space:nowrap">4Q-2025;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presented <U>preclinical data for ZW1528</U>, a novel <FONT STYLE="white-space:nowrap">IL-4R&#945;</FONT> x <FONT
STYLE="white-space:nowrap">IL-33</FONT> bispecific molecule designed to address respiratory inflammation, and the first program from our ADVANCE research strategy; and, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Through a series of scientific<U> publications and presentations</U>, outlined additional preclinical data
supporting the potential therapeutic benefit of clinical programs and investigational new drug (IND) candidates in our solid tumor ADC portfolio (ZW191, ZW251, and ZW327) and our Trispecific <FONT STYLE="white-space:nowrap">T-cell</FONT> Engager
(TriTCE) <FONT STYLE="white-space:nowrap">Co-stim</FONT> platform (ZW209). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Corporate: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthened our board of directors through the addition of three new members: Oleg Nodelman, Robert E. Landry,
and Greg Ciongoli; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthened our leadership team through the addition of Dr.&nbsp;Sabeen Mekan as Senior Vice President, Clinical
Development, Dr.&nbsp;Adam Schayowitz as Acting Chief Development Officer and Mr.&nbsp;Scott Platshon as Acting Chief Investment Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully <U>completed $60.0 million&nbsp;in share repurchases</U> under the Company&#8217;s initial Share
Repurchase Program announced in August 2024; and, </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Evolved our strategy</U> to focus on building a diversified portfolio of revenue-generating healthcare assets
and wholly-owned product candidates. The new strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2026 Milestones&nbsp;&amp; Priorities Expected to Drive Long-Term Value Creation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#8217; evolving strategy is designed to compound long-term value by integrating royalty growth, strategic acquisitions, and internal R&amp;D
innovation, all supported by a strengthened financial foundation and thoughtful capital allocation. The Company expects meaningful, predictable and durable cash flows from its partnered programs, including <I>Ziihera</I> and pasritamig, as these
therapeutics continue through late-stage development and commercialization. These projected revenues provide greater flexibility in capital allocation, enabling Zymeworks to balance reinvestment into its royalty and asset portfolio, to target
investment in innovative internal R&amp;D, and to continue returning excess capital to shareholders. The Company intends to pursue partnership and acquisition opportunities based on strategic fit and long-term value creation with time and
optionality rather than near-term cash needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This evolution also formalizes Zymeworks&#8217; integrated operating model, which pairs a robust internal
R&amp;D engine with a growing portfolio of revenue-generating licensed products. The Company&#8217;s proven ability to evaluate, prioritize, and advance its own pipeline, independently and through valuable partnerships, provides a framework for
assessing potential acquisitions that may include cash-generating products, undervalued programs, or assets with attractive financial structures. By combining internal innovation with strategic asset aggregation, Zymeworks aims to scale a model that
has historically driven its success, and seeks to maximize sustainable value creation and reinforce its differentiation from other healthcare royalty and asset aggregators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Our internal R&amp;D engine has demonstrated the depth and breadth of novel programs and technologies it can develop, including <I>Ziihera</I> and
pasritamig. As we evolve our strategy, we remain committed to disciplined, data-driven portfolio management and investment decisions designed to prioritize high internal rate of return opportunities,&#8221; said Galbraith. &#8220;Our global
development capabilities enable us to rapidly generate high-quality clinical data, while our integrated model ensures helps us identify, partner, or acquire the right assets to build a durable and diversified portfolio. We believe this is the
foundation for long-term sustainable value creation at Zymeworks.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transition to an integrated partnership strategy requires a change in scope
and priorities for our R&amp;D activities within the ADVANCE R&amp;D strategy as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In our current ADC portfolio, we intend to continue to conduct our ongoing Phase 1 clinical studies for ZW191 and
ZW251 during 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to advance our other ongoing ADC research efforts, including future clinical development of ZW220,
ZW327, and ZW418 (a biparatopic PTK7-targeting ADC incorporating a novel <FONT STYLE="white-space:nowrap">pan-RAS</FONT> inhibitor payload) into clinical studies only with partnerships and collaborations and/or external funding becoming available;
and, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Beyond 2026, we intend to focus our future ADVANCE research efforts solely on multispecific antibody and
engineered-cytokine platforms, funded partially with early-stage partnerships and collaborations. We expect ZW1528 to be the first of our ADVANCE R&amp;D programs to enter clinical studies in 2026. We intend to continue actively sharing
peer-reviewed publications and data across preclinical and clinical programs. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company anticipates the following clinical development milestones from its R&amp;D pipeline: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The global Phase 1 clinical trial investigating ZW191 in solid tumors is ongoing with dose optimization of ZW191
in ovarian cancer. Additional data from the Phase 1 trial is anticipated to be presented at a major medical meeting in 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The global Phase 1 clinical trial investigating ZW251 in solid tumors is actively recruiting. The Company
presented a <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Trial-in-Progress</FONT></FONT> poster for ZW251</U>, at ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January&nbsp;9, 2026; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">INDs for multispecific programs, ZW209 and ZW1528, remain on track for submission in 2026, as we continue
evaluating partnership opportunities before the commencement of clinical studies; and, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Development of wholly-owned preclinical candidates from our multispecific antibody portfolio to provide for one
planned IND filing per annum commencing in 2028. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(zanidatamab-hrii) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Late-breaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-GEA-01</FONT></FONT>
<U>clinical data presented</U> at ASCO GI by partner Jazz Pharmaceuticals on January&nbsp;8, 2026. The study found: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Both investigational arms,<I>&nbsp;Ziihera</I>&nbsp;plus tislelizumab and chemotherapy
and<I>&nbsp;Ziihera</I>&nbsp;plus chemotherapy, led to a statistically significant and clinically meaningful prolongation of progression-free survival (PFS) with approximately 35% reduction in the risk of disease progression or death versus
trastuzumab plus chemotherapy. This resulted in a median PFS of more than one year, representing a greater than four month improvement compared to the control arm. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ziihera</I>&nbsp;plus tislelizumab and chemotherapy demonstrated a statistically significant and clinically
meaningful overall survival (OS) benefit with a median OS of more than two years (26.4 months), the longest reported in a Phase 3 trial in GEA, representing a greater than seven-month improvement in median OS and a 28% reduction in the risk of death
versus trastuzumab plus chemotherapy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At this first interim analysis,<I>&nbsp;Ziihera</I><I></I>&nbsp;plus chemotherapy showed a median OS of more than
two years, with a strong trend toward statistical significance, favoring<I>&nbsp;Ziihera</I>&nbsp;plus chemotherapy versus trastuzumab plus chemotherapy. An additional planned OS interim analysis for<I>&nbsp;Ziihera</I>&nbsp;plus chemotherapy is
currently expected in <FONT STYLE="white-space:nowrap">mid-2026.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The OS and PFS benefits were generally consistent across major prespecified subgroups including geographic region
and <FONT STYLE="white-space:nowrap">PD-L1</FONT> status for both investigational arms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on the topline results from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-GEA-01,</FONT></FONT> Jazz plans to submit a supplemental Biologics License Application in <FONT STYLE="white-space:nowrap">1H-2026</FONT> for zanidatamab in the U.S. as
first-line treatment for HER2+ locally advanced or metastatic GEA; and, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks has the potential to receive substantial near-term milestone payments related to future anticipated
regulatory approvals in GEA totaling $440.0&nbsp;million, as follows: U.S.&#8212;$250.0&nbsp;million; EU&#8212;$100.0&nbsp;million; Japan&#8212;$75.0&nbsp;million; China&#8212;$15.0&nbsp;million. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Share Repurchase Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2025, the Board of Directors authorized a new share repurchase program providing the ability to repurchase up to $125.0&nbsp;million in common<B>
</B>stock. The program underscores our confidence in Zymeworks&#8217; long-term growth prospects and helps enhance shareholder value by reducing share count, while maintaining cash resources for operations and growth investments and preserving
financial flexibility for strategic opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company has utilized approximately $19.0&nbsp;million of this approved repurchase program
to acquire 727,271 shares of the Company&#8217;s common stock at an average price of $26.07 (exclusive of commission expense and estimated excise tax). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operational and Cash Runway Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our adjusted gross
operating expense <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> guidance for combined adjusted research and development (R&amp;D) expense <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> and adjusted general and administrative (G&amp;A)
expense <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> (excluding stock compensation expense) outlines a disciplined framework of approximately $300.0&nbsp;million in aggregate adjusted gross operating expenditures
<FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> over a three-year period ending December&nbsp;31, 2028. We expect a greater proportion of adjusted gross operating expense <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> to be incurred in 2026
and decline in 2027 and 2028, reflecting a deliberate and measured investment across R&amp;D and G&amp;A aligned with clearly defined strategic priorities. This outlook reflects current expectations, underscores our continued focus on cost
discipline and capital allocation rigor, and does not include any potential acquisition-related expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2025, the Company
had cash resources of approximately $270.6&nbsp;million (unaudited), consisting of cash, cash equivalents, and marketable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on current
operating plans and our existing cash resources, and assuming full execution of the $125.0&nbsp;million share repurchase plan and receipt of anticipated regulatory milestone payments of $440.0&nbsp;million associated with potential regulatory
approvals of <I>Ziihera</I> in GEA in the United States, Europe, Japan, and China, we believe we are positioned to fund planned operations beyond 2028. This anticipated cash runway does not take into account any contribution from additional future
milestone payments or royalties related to <I>Ziihera</I>, other current licensed product candidates or contributions from future partnerships and collaborations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>J.P. Morgan Healthcare Conference Presentation and Webcast </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management will participate in the J.P. Morgan Annual Healthcare Conference taking place in San Francisco, California, from January <FONT
STYLE="white-space:nowrap">12-15,</FONT> 2026, and present on January&nbsp;14, 2026, at 3:00 pm PT. The presentation and webcast will be available on <U>Zymeworks&#8217; website</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to reporting financial information in accordance with U.S. generally accepted accounting principles (GAAP) in this press release, we have elected
to present selected <FONT STYLE="white-space:nowrap">non-GAAP,</FONT> or adjusted, financial measures on a forward-looking basis. A reconciliation of anticipated adjusted gross operating expense, adjusted research and development expense, and
adjusted general and administrative expense to the most directly comparable GAAP measures is not available without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, and we are also unable to predict the
probable significance of such adjusted measures. Accordingly, in reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> we have not provided a reconciliation for the adjusted gross
operating expense, adjusted research and development expense, and adjusted general and administrative expense guidance provided in this press release. Zymeworks believes that estimated adjusted gross operating expense, adjusted research and
development expense, and adjusted general and administrative expense, which are <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures, may be helpful to investors because they provides consistency and comparability with financial
performance across periods. These <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are not defined by GAAP and should not be considered as alternatives to operating expenses, research and development expenses, and general and
administrative expenses or any other indicators of Zymeworks&#8217; performance required to be reported under GAAP. In addition, other companies, including companies in Zymeworks&#8217; industry, may calculate similarly titled <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> or adjusted measures differently or may use other measures to evaluate their performance, all of which could the reduce the usefulness of adjusted gross operating expense, adjusted research and development
expense, and adjusted general and administrative expense as financial measures. As defined by Zymeworks, adjusted gross operating expense represents the aggregate of adjusted research and development expense and adjusted general and administrative
expense, each of which excludes stock-based compensation expense for equity- and liability-classified equity instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&nbsp;is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel,
multifunctional biotherapeutics to improve the standard of care for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> diseases, including cancer, inflammation, and autoimmune disease. The
Company&#8217;s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (zanidatamab-hrii) and
other licensed products and product candidates, such as pasritamig. In addition,&nbsp;Zymeworks&nbsp;is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative
medicines.&nbsp;Zymeworks&nbsp;engineered and developed <I>Ziihera</I>, a HER2-targeted bispecific antibody using the Company&#8217;s proprietary Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology and has entered into
separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and&nbsp;Jazz Pharmaceuticals Ireland Limited&nbsp;granting each exclusive rights to develop and commercialize zanidatamab in different territories.&nbsp;Zymeworks&nbsp;is
rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company&#8217;s
complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further
leveraged through strategic partnerships with global biopharmaceutical companies. For information about&nbsp;Zymeworks, visit&nbsp;www.zymeworks.com&nbsp;and follow @ZymeworksInc on X. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#8220;forward-looking statements&#8221; or information within the meaning of the applicable securities legislation, including
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to
Zymeworks&#8217; expectations regarding implementation of its strategic priorities and the anticipated benefits thereof, including shareholder returns and the anticipated manner of such returns; implementation of its long-term strategy to maximize
value creation; preliminary and unaudited estimates of its cash, cash equivalents, and marketable securities; anticipated sufficiency of existing cash resources, assuming full execution of the share repurchase plan and receipt of anticipated
regulatory milestone payments associated with potential regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China, to fund Zymeworks&#8217; planned operations beyond 2028; expectations regarding cash flows from partnered
programs, including Ziihera and pasritamig; Zymeworks&#8217; ability to balance reinvestments into its royalty and asset portfolio and internal R&amp;D and return to stockholders; implementation of its evolving asset aggregation strategy, including
existing and potential future royalty streams and existing and potential new partnerships; the anticipated benefits of its collaboration agreements, including Zymeworks&#8217; ability to receive any future milestone payments and royalties
thereunder; statements relating to potential milestone payments upon regulatory approvals of Ziihera in GEA and the timing thereof; statements that relate to the expected contributions of personnel to Zymeworks&#8217; strategic goals; statements
that relate to Zymeworks&#8217; ability to execute the share repurchase plan, in whole or in part; expected timing and amount of repurchases; Zymeworks&#8217; ability to pursue its business objectives following repurchases under the share repurchase
plan; anticipated capital allocation strategy; industry opportunities for acquisition of new revenue streams or collaborations; the timing of and results of interactions with regulators; Zymeworks&#8217; clinical development of its product
candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies and the related data; anticipated preclinical and clinical data presentations; expectations regarding future regulatory filings and approvals and
the timing thereof; expected financial performance and future financial position, including anticipated adjusted gross operating expense <FONT STYLE="white-space:nowrap">(non-GAAP),</FONT> adjusted research and development expense <FONT
STYLE="white-space:nowrap">(non-GAAP)</FONT> and adjusted general and administrative expense <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT> for the three-year period ending December&nbsp;31, 2028, excluding any potential acquisition-related
expenditures; the commercial potential of technology platforms and product candidates; Zymeworks&#8217; ability to satisfy potential regulatory and commercial milestones with existing and future partners; the timing and status of ongoing and future
studies and the release of data; anticipated continued receipt of revenue from existing and future partners; Zymeworks&#8217; early-stage pipeline; Zymeworks&#8217; ability to execute new collaborations and partnerships and other information that is
not historical information. When used herein, words such as &#8220;plan&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;may&#8221;, &#8220;continue&#8221;, &#8220;anticipate&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;on
track&#8221;, &#8220;progress&#8221;, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks&#8217; current expectations and various assumptions. Zymeworks believes there is
a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various
factors, including, without limitation: any of Zymeworks&#8217; or its partners&#8217; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable;
Zymeworks may not be able to successfully execute the share repurchase plan; the anticipated benefits of the share repurchase plan may not be realized; Zymeworks may not achieve milestones or receive additional payments under its collaborations;
regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory
delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and
other health crises on Zymeworks&#8217; business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#8217;
behalf; zanidatamab may not be successfully commercialized; Zymeworks&#8217; business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully
implemented; Zymeworks&#8217; evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&amp;D operations;
ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#8217; or its collaborators&#8217; product candidates; data providing early validation of our antibody drug conjugate platform and next generation
pipeline programs may not be replicated in future studies; Zymeworks&#8217; assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new
partnerships or strategic collaborations; and the factors described under &#8220;Risk Factors&#8221; in Zymeworks&#8217; quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov
and www.sedarplus.ca). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, we are in the process of finalizing our financial results for the fourth quarter and fiscal year 2025, and therefore
our finalized and audited results and final analysis of those results are not yet available. The preliminary expectations regarding <FONT STYLE="white-space:nowrap">year-end</FONT> cash, cash equivalents, and marketable securities are the
responsibility of management, are subject to management&#8217;s review and actual results could differ from management&#8217;s expectations. The actual results are also subject to audit by our independent registered public accounting firm and no
assurance is given by our independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December&nbsp;31, 2025, based on the
foregoing estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be
correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law,
Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor inquiries: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shrinal Inamdar </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@zymeworks.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media inquiries: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@zymeworks.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d97670dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g97670g0111231102132.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Investment industry veteran Mr.</I><I></I><I>&nbsp;Brian Cherry appointed to Board of Directors</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dr.</I><I></I><I>&nbsp;Sabeen Mekan to transition to Chief Medical Officer effective
February</I><I></I><I>&nbsp;1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating Officer</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Five new Vice Presidents appointed, underscoring our commitment to leadership development</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vancouver, British Columbia (January 12, 2026)</B> &#8211; <U>Zymeworks Inc</U>. (Nasdaq: ZYME), a biotechnology company managing a
portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the
capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company&#8217;s corporate strategy announced in November. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;At Zymeworks, we recognize that our greatest asset is our people. Ensuring that we continue to have the right set of key skills and experience within
our Board of Directors and leadership team is critical for successful execution of our current strategy and driving long-term shareholder value. Elevating talented individuals at Zymeworks recognizes their strong performance for the Company, our
continued confidence in their abilities and the emphasis we place on cultivating leaders from within,&#8221; said Kenneth Galbraith, Chair, Chief Executive Officer, and Acting Chief Financial Officer of Zymeworks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors Strengthened to Support Future Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Cherry has been appointed to the Board effective January&nbsp;12, 2026 to bring the current Board to nine directors. Mr.&nbsp;Cherry has spent more than
25 years investing in and helping build businesses across a wide range of industries including healthcare, industrials, business services, financial services, and consumer products. He has led buyout and growth equity investments in companies
totaling over $25&nbsp;billion in enterprise value. Previously, Mr.&nbsp;Cherry was a Managing Partner at Oak Hill Capital, a private equity firm. His board experience includes over a dozen private and public companies, the U.S. Air Force Academy
Foundation, and the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania. Mr.&nbsp;Cherry earned his BA from Princeton University and his MBA from The Wharton School at the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Galbraith added, &#8220;Over the past year, we have taken deliberate steps to streamline the Board, reducing its size from twelve to nine directors,
while ensuring that the collective skills and experience of the Board are well aligned to provide effective oversight of the Company&#8217;s new corporate strategy. Brian brings complementary expertise to the Board, particularly in capital
allocation and strategic acquisitions, which we believe will support disciplined execution and long-term shareholder value creation.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Cherry is the fourth new director appointed to Zymeworks&#8217; Board over the past twelve months, joining Mr.&nbsp;Oleg Nodelman, Mr.&nbsp;Greg
Ciongoli, and Mr.&nbsp;Robert&nbsp;E. Landry. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Appointments and Transitions Position Company for Next Phase of Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer with expanded responsibilities beyond his current leadership
of Technology and Manufacturing Operations, Quality, and Alliance/Program Management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Sabeen Mekan has been promoted to Senior Vice President
and Chief Medical Officer (CMO) effective February&nbsp;1, 2026, with overall responsibility for our clinical development, regulatory affairs, pharmacovigilance/patient safety, and clinical operations. Dr.&nbsp;Jeff Smith, our current CMO, will be
retiring effective January&nbsp;31, 2026, while continuing to provide services as an adviser for a transitional time period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Leone Patterson,
our Chief Financial and Business Officer and Mr.&nbsp;Daniel Dex, General Counsel, will both be departing from their roles at Zymeworks during the first quarter of 2026. The Company has commenced a comprehensive search for a permanent Chief
Financial Officer with the experience required to support the Company&#8217;s next phase of development. Mr.&nbsp;Galbraith has assumed the role of Acting Chief Financial Officer until a replacement is secured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the following individuals have been promoted or appointed to the leadership team: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Laura O&#8217;Connor, Senior Vice President and Chief Human Resources Officer </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Bijal Desai, Senior Vice President, Finance </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Lindsey Foulkes, Senior Vice President, Corporate Development and Strategy </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Charles Chen, Vice President, Translational Sciences </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Shrinal Inamdar, Vice President, Investor Relations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Diana Papove, Vice President, Corporate Communications </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms.&nbsp;Victoria Spencer, Vice President, Treasury and Tax </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Lingxing Zheng, Vice President, Regulatory Affairs </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;These outstanding individuals have consistently demonstrated exceptional leadership abilities, commitment to our vision, and a deep understanding of
both our strategic objectives and our commitment to bringing meaningful medicines to patients worldwide,&#8221; stated Mr.&nbsp;Galbraith. &#8220;These leadership changes reflect the alignment of management resources to effectively execute against
our strategic objectives in order to drive long-term shareholder value at Zymeworks.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information on the background and experience of
these individuals is available on the Company&#8217;s website at <U>www.zymeworks.com.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&nbsp;is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional
biotherapeutics to improve the standard of care for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> diseases, including cancer, inflammation, and autoimmune disease. The Company&#8217;s asset and
royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (zanidatamab-hrii) and other licensed products
and product candidates, such as pasritamig. In addition,&nbsp;Zymeworks&nbsp;is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medicines.&nbsp;Zymeworks&nbsp;engineered and developed <I>Ziihera</I>, a HER2-targeted bispecific antibody using the Company&#8217;s proprietary Azymetric<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and&nbsp;Jazz Pharmaceuticals Ireland Limited&nbsp;granting each exclusive rights to
develop and commercialize zanidatamab in different territories.&nbsp;Zymeworks&nbsp;is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics
targeting novel pathways in areas of significant unmet medical need. The Company&#8217;s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop
highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about&nbsp;Zymeworks, visit&nbsp;www.zymeworks.com&nbsp;and
follow @ZymeworksInc on X. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#8220;forward-looking statements&#8221; or information within the meaning of the applicable securities legislation, including
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to
Zymeworks&#8217; expectations regarding implementation of its strategic priorities and the anticipated benefits thereof; implementation of its evolving asset aggregation strategy, including existing and potential future royalty streams and existing
and potential new partnerships; statements that relate to the expected contributions of personnel to Zymeworks&#8217; strategic goals and long-term shareholder value; anticipated capital allocation strategy; industry opportunities for acquisition of
new revenue streams or collaborations; the commercial potential of technology platforms and product candidates; Zymeworks&#8217; early-stage pipeline and other information that is not historical information. When used herein, words such as
&#8220;plan&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;may&#8221;, &#8220;continue&#8221;, &#8220;anticipate&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;on track&#8221;, &#8220;progress&#8221;, and similar
expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks&#8217; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements
as a result of various factors, including, without limitation: any of Zymeworks&#8217; or its partners&#8217; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not
commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws
and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs,
budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks&#8217; business, research and clinical development plans and timelines and results of operations,
including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#8217; behalf; zanidatamab may not be successfully commercialized; Zymeworks&#8217; evolution of its business strategy related to anticipated
and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks&#8217; business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in
actively managing and/or aggregating revenue-generating assets alongside its active R&amp;D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#8217; or its collaborators&#8217; product
candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks&#8217; assumptions and estimates regarding its financial condition, future
financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under &#8220;Risk Factors&#8221; in Zymeworks&#8217; quarterly and annual
reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance
they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may
be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor inquiries: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shrinal Inamdar </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT
STYLE="white-space:nowrap">678-1388</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@zymeworks.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media inquiries: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT
STYLE="white-space:nowrap">678-1388</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@zymeworks.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>zyme-20260106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/12/2026 4:26:25 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:zyme="http://www.zymeworks.com/20260106"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.zymeworks.com/20260106"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20260106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20260106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>zyme-20260106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/12/2026 4:26:25 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>zyme-20260106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/12/2026 4:26:25 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20260106.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g97670g0111114420980.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97670g0111114420980.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& )P# 2(  A$! Q$!_\0
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D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g97670g0111231102132.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97670g0111231102132.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& )P# 2(  A$! Q$!_\0
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D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  06,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d97670d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d97670d8k.htm">d97670d8k.htm</File>
    <File>zyme-20260106.xsd</File>
    <File>zyme-20260106_lab.xml</File>
    <File>zyme-20260106_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d97670d8k.htm": {
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20260106",
   "dts": {
    "inline": {
     "local": [
      "d97670d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "zyme-20260106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20260106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20260106_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-01-06_to_2026-01-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d97670d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-01-06_to_2026-01-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d97670d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zymeworks.com//20260106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-26-010480-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-010480-xbrl.zip
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M^E$O" <R!GS!GK;JS7:]O6UU4@=\R'5D\&-:/[OUC58*2QC<G;34 A3QJ5/
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M"2M5Z=B99;M3W)[2_)'P>[2YP0#^Y'H*GG5@J,=S_ UT0;7JFZVMC:U*:/U
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MW79KYR 2L?+4$ $@?() #6T-+T'WF !V* $@A'%SG'HL!+F^@H0_&@X]("/
M].<'Y2>0+F HLNLW)&$#7R7S%0!B3_#9$?  E%["DY$YDWEU "_K]'0:IJT<
M'O=5]QN=\\DAZ + _-'N[P3WHJ.\X [W#1_B[DYG*W0^3J0M>JZ'%.-&0#ZQ
M\AW8]SB K1\D7BQ]%221-Q(1<).H-Z(1] M!!P#&!HT^?[0.$1+H!W#*'YEG
MO<"#2>)[J,>X:!A'^Y78M/U8E_FB7.(M*Y@I<X1G3O)Q9WS!63^39K%2YL#>
M?'LP6>@B4DX0#/\,W1CV$1T0B:]-SFAN%;03!%Y'PA[&@'&V\&CC/NR!Z#@8
MEQT/4R9X718^B#P*B+FY]=A@&E8 '!M88FB=^E\F@%:;[2V-TH5S=CQ>7VWM
MB.-/EZ*]T6Q PX)I7Z+@O.+Y(O#\"IAY%W;!OSD#1@C<T%L>DF^\9"3/  5=
M,Z3&,7RJQ&AMRGJK;81&1@RY2!-#"E-[:V\V&]SCFJ5BOE+-TJGF(E0H&3!Z
MFR+M4."'Y[W>(PR(F:EG\R53SU14!HC6NQ9(#8E,DRDS4)Q3;Z]VUA9+<]SG
M*]4])]6=1E&BPB>AO:U7VGL4[6VH^N9J=[&TI_N<F?86;4%:>BN;:BH$8V]8
M&>**C,+8;[#::G/M-<+IAXAP&G=?S^!%J5C!& W,=42\C$/9:\RIY.CC;E]T
M/1E%"SDQ>33,OK<S].M0(B$^^^GYU6@ CU:CQ00O_##;\U6'[A+Z*BV5GGVS
M E\ [<.,,@DS(=3A&8,R*]T*+"1'K7:'.,0<YRK;*X>H]0%(KN*@^ZTFAC(4
MM])+E/BYV4!4:XDA)K?V2T]OG^;DK@H.FOJ9^.8 PL[*X7_^?7;RO2W/;+-1
MYQX5\5_4PI$*QX[H=W:!E8(&]55&COP?HX(XD^$W%8LO7XY+ ?-4&N&I[Z"2
MK$1G)+ITO@ ]?@,*5A1+6'#JNY$ +1<4;1ST1MR$P5W<1UU[B(Y^&0E']5R?
MLP;8;=K<$N.Y25E*TH98Q>W=.2#7J6GL4K[!$/,-\'QJ1H6]W:FGWJG9\J&F
M=VIFA\K[6/_6-!M+/61<.3PI!_G??MIM[8%A-SFTPKS\F=X]YE>79W#N33 X
MEPJDT]X$[,2SX5)4=\>.KOJ R,H#0P@0V0_(+$HB1:T 7OJ #,N'N'3VQ<G]
M"!\:RQOAX'<N#(U$X</\X$FH;MT(W@/RD'X7';"RV\4P?FR,A40<&3H1'XTY
M$VVRC569VF0V4C<T,J2PKS#56K.D\5<>U/Y0%0%RY[9OWI1B9DL-QC 3?[(4
MEXZ"O0?%Q;N3HPAU0@#:FW?]5,<!8S4(]W_:HW\'9CW#>]L@[7I*ABCR^F3R
MO9ER.+[8F@]OBIZZ#^>7'T\NZ\?G7[X<75R=[)L/+\%3UVK-Z*J;'+%T&JL!
M!IHT6P?M1K,]:S35D[O,)JGD//JEBA(OIGBQ<^!5VB,&'$=\2IG1<0#,$1\T
MQ$.<4MN+8-OGOL@EUK9:G%E;$_D42K&*+ _WI-T\.$X%8+O=.EB#Y?C 3;O
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M54'U:QL@L(],@+XR0-;IAC3AN%2MP3?0;$E KMXH'X2L)P9*T1IAW A]ZGU
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M?$3N5<UP+Z]^CS)5CP[5H3/>:3TG B(PD1L\)V ;L92WL?TY 92HAMM LF2
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MN2=F"KO:QV4[I9#I5:^[;$(UD(;$J(A7&/!'R6" /MN';X#6/E-GE"& 8TL
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M%%78%3Z;-;4QN4>*SG;FV_-2;%K-RG#F"A<?6<-?FN'3#+<2.LDJ!^4QRZ#
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M$PTS8X[D8W)&>>/?=<+UPZ]!XW%9B0_,S)PRI8]9'5Y[.F59C];FCT%(F_U
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ME?W[]>7@V/S]_=G)S>M?UK8V-W]:X_5<B2R?1TK\(M9F<JQZPU3)#[TPSL)
M[<O;) STBR?FXZ<_E9NZ.:G]N//3FOA#WP(<BKT11IZ??]C:?='VV5;MLY8)
MW(&J[R) 57[5QRNJER,6@]<#3_KPY=GA99(!P-PJ<3F1F1([L+A?+][>6,(Q
M"7/5RV;25_MQ<I=*6-^]+[P^O3K[Z^)M[]7IH+<)E W?/]3_$ZG*BBC/""C_
M"L.)2N7+)V>XE)?7[UJ@<N_I3P?B5J5YZ,NH1[1KGX\T56,X4?CH4 \@UC_)
M. QD+J=RV)ND8;@APEB,PC3+>X@K E:VW9N9+:_C7_]CH]L9RRQ/$Y4ELPG
MC(R$#%2<^#+UPQA.3JS#3C;$#):.B!@(F8O!]?&%>'4F<&HB W2W\)\K_ ]B
M13M=6R'9/Q#)WLU$GH@?=W<W^YL&V/E_O&08* J3&($5_JBR/ %8G4D@]3%@
MB@*8#X=PW##&4 DETQA@,%611%B$AX (!?PE2>?=CIS-TN161IE(1@:_<%R
M8/Q?/E'B71SBA]<Y?)]YXK1(DYGRQ&]R)F./&,?Q)(SE"K)7D'TO9!\G4X":
MN;A34:0):Q(S5*J/RB]R)6(8(&,192Y\>#\IXB",QR)*XG$/Y)JI '@ME!C.
M 4+A+7@5?TZ3N8SRN1BGR5T^\;J=S,HYTO]7$?)<&4.L#TL+XP)FQB'2&&CX
MU<]R.CLX@0<Q( 2^NX+H%43?"]$_;FT_74ZELXE,%1#=69'Z)#3-(AD#%,8
MV#Y!H'B;W*KI4)'8_53(6QE&4E/P5 6%KWB0;L>';_(57*[@\GY**[.))WSX
MKU! _8!DHG# U ^&_Z!R@K ,B*Y6 4$ (&G@8S@%NAG-Q8_;>YO]9TM N]M9
M+V)9!"@?; A)0YPHGT"Y[;.=+8\@W$.Z/@R1\-^%^036!-)Z."/YI!1.VF0;
M1XJ9)3D\"E'Z7BS#>,!69LHWG\!K "Y\*FD1W\DY2$CS!(X$EO5\"5ZM-. 5
M8M5$&((GTO!0OT-!^;?^95^\2=(QD/=!'!< FJ]!.\PG/C* XR0>J50!R1?
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M;6\>D+1T!WP'8""\37)]+K"I.!NAC9O,-G2H9#XR9^/1]UL'(I-A('Y7<:R
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MEG%_FK?L3!)'P*3O5<[@2C=W(_,(J/PB1594=0@2[62YLR+ \I])G\9OT>.
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MK Y4/:JFF, $$ON$Y@2A9LR+5"5@JD OYA*8P;=6)?W>,021(*QPMJ7Y\LH
MZ:7[]^E0G.-+NVC4=.OD[!?X8)^\[_<$_[^?NUBY*T U79$?/0J"Z9$"NT(P
MG<[EHJ!P=2NG0=Y=B>NSW[$=3S?J?OEP8?>'5_Q?-UJO(]SCTP\WIU?_[XX7
MB/-\;>K[TOA<D-=+)I\?U.=27,)]LLJ_=3[S>U"A!A)+V:2&%?VG:247?L&
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MT5:1[IZ[1_F=RDARWK[?+&*X)T)2SDYZP_Y1#P@+>439[*2WDEX@0TI[().
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M,RI.?&3H0(CJ$GS1M@7Y/VR%7 5[J;G' O/HZ_J(>3,/<F+)WU!+ 0(4 Q0
M   ( %B$+%S#UK@'TRH   4- 0 -              "  0    !D.3<V-S!D
M.&LN:'1M4$L! A0#%     @ 6(0L7.Z1LEW'*P  PM0  !
M ( !_BH  &0Y-S8W,&1E>#DY,2YH=&U02P$"% ,4    " !8A"Q<!1+IED87
M  "16P  $               @ 'S5@  9#DW-C<P9&5X.3DR+FAT;5!+ 0(4
M Q0    ( %B$+%Q=HOV0/P,  $T+   1              "  6=N  !Z>6UE
M+3(P,C8P,3 V+GAS9%!+ 0(4 Q0    ( %B$+%RSL] K? 8  +=&   5
M          "  =5Q  !Z>6UE+3(P,C8P,3 V7VQA8BYX;6Q02P$"% ,4
M" !8A"Q<=8(O"L,$   _+   %0              @ &$>   >GEM92TR,#(V
B,#$P-E]P<F4N>&UL4$L%!@     &  8 ? $  'I]      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d97670d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20260106.xsd" xlink:type="simple"/>
    <context id="duration_2026-01-06_to_2026-01-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2026-01-06</startDate>
            <endDate>2026-01-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-548">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-01-06_to_2026-01-06"
      id="Hidden_dei_EntityCentralIndexKey">0001937653</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-559">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-560">2026-01-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-561">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-562">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-563">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-564">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-565">108 Patriot Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-566">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-567">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-568">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-569">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-570">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-571">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-572">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-573">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-574">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-575">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-576">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-577">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-578">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-01-06_to_2026-01-06" id="ixv-579">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
